



of y



CONFERENCES It's not too late to join us virtually or in person at The Royal Institution in London October 5-6 for the <u>International Conference on Newborn</u> <u>Sequencing</u>. Register using <u>this link</u>.



PRESS Since the conclusion of the <u>BabySeq 1 Project</u>, the team has followed 17 families who were identified to have an unanticipated monogenic disease risk. This work has been highlighted by several news outlets including <u>USA</u> <u>Today</u>, <u>GenomeWeb</u>, and <u>STAT</u>.



PUBLICATIONS The Sanford Imagenetics team <u>published their</u> <u>latest paper</u> in collaboration with G2P describing the positive attitudes primary care providers have towards pharmacogenomic testing compared to speciality care providers. Their findings emphasize the importance of provider education and its effectiveness at increasing confidence to utilize PGx testing in clinical care.



BLOG Addressing stark, deeplyrooted racial disparities in healthcare has to be a priority in clinical research. Polygenic risk scores might be one tool to improve disease screening and move us beyond racebased medical decision-making and toward more equitable health outcomes. <u>Read Genomes2Veterans'</u> <u>plans</u> to address equitable screening for prostate cancer risk.



G2P TRAINEES We welcomed our summer cohort of research trainees for a collaborative learning experience. Students were <u>paired</u> with mentors to work alongside our core research team to further develop our projects and gain a deeper understanding of our mission to accelerate the implementation of precision medicine.



AWARDS In honor of the 10 year anniversary of Ariadne Labs, Director of Precision Population Health (PPH), Dr. Robert C. Green, Director of Project Management, Carrie Blout Zawatsky, and Director of Strategic Planning, Nic Encina presented on the <u>lessons learned</u>, progress, and future of PPH.



PRESS Each month, the editors of ASHG's Human Genetics and Genomics Advances interview an early-career researcher who has published work in the journal. This month they feature G2P collaborator Dr. Nina Gold to discuss her paper <u>Phenotypes of undiagnosed adults with actionable OTC and GLA</u> <u>variants</u>. The full interview "Inside HGG Advances: A Chat with Nina Gold" is <u>available to read here</u>.



Your gift makes a difference. Please consider<u>supporting</u> our work.

